Aditxt Inc. (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, announced that it is working with Riverside Management Group LLC, a merchant banking firm providing investment banking advisory services; RMG will be supporting Aditxt’s strategic growth and revenue generating plans for its subsidiary Pearsanta Inc., as well as other Aditxt programs. The company noted that Pearsanta was formed to accelerate the growth of AditxtScore(TM) and focused on expanding the market through new offerings and customer acquisitions. A AditxtScore is the company’s exclusive platform designed offer a personalized profile of the immune system based on the body’s ability to respond to viruses, bacteria, allergens and more. “We are pleased to partner with Riverside Management Group and its team of investment and financial advisory experts,” said Aditxt cofounder, chair and CEO Amro Albanna in the press release. “We’ve mandated Riverside Management Group to focus on strategic, growth-driven M&A opportunities for Pearsanta and other current and future programs. We believe Pearsanta is well-positioned to achieve meaningful financial milestones in 2023 and look forward to sharing highlights with our valued Aditxt shareholders.”
To view the full press release, visit https://ibn.fm/QUy3V
About Aditxt Inc.
Aditxt is an innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune modulating technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.